Bumps on the face; opioids and alcohol; dysmorphic facial features in 6-month-old boy . . . questions on these and other topics in this quiz.
Question 1:
These slowly growing bumps appeared on the face of a 56-year-old man.
Answer and new question on next page »
The correct answer is c. Sebaceous hyperplasia.
For a discussion of the case, click here.
Question 2:
This CT scan from a 46-year-old African American woman with HIV infection shows bilateral multiple masses in the parotid glands.
Answer and new question on next page »
The correct answer is b. Parotid manifestations of HIV infection have a malignant course.
For a discussion of the case, click here.
Question 3:
Answer and new question on next page »
The correct answer is b. False.
For a discussion of the case, click here.
Question 4:
A 35-year-old man has been treated for hypertension and a slightly elevated creatinine level. A fasting lipid panel 3 years earlier revealed a total cholesterol level of 246 mg/dL, but he declined treatment. His blood pressure has been elevated since he was 23 (then 150/98 mm Hg); he has been taking lisinopril and hydrochlorothiazide. His blood pressure is now 148/100 mm Hg, and his BMI is 24 kg/m2. ECG findings are consistent with LV hypertrophy and “strain pattern.” His estimated GFR is 59 mL/min, which-together with data from 6 months earlier-classifies him as having stage 3 chronic kidney disease. A renal ultrasonogram was obtained.
Answer and new question on next page »
The correct answer is d. All of the above.
For a discussion of the case, click here.
Question 5:
Mowat-Wilson syndrome was diagnosed in this 6-month-old boy with dysmorphic facial features, ear anomalies, and hypospadias.
Answer on next page »
The correct answer is c. Seizures develop in about 25% of affected patients, usually by 2 years of age.
For a discussion of the case, click here.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.